知乎-W(02390.HK)成ChatGPT概念股 現飆逾四成
知乎-W(02390.HK)今日高開14.84%,最高見34.5元。現報32.85元,升41.29%,成交111.26萬股,涉資3,371.74萬元。
據內地主流機構預測,知乎仍為內容社區將成為ChatGPT概念股之一,因ChatGPT是建立在龐大數據量的訓練基礎上,然後通過引入「手動標註數據」以及「強化學習」來調整預訓練語言模型,從而大幅提升回答信息的準確性。機構認為,知乎憑藉多年對高質量內容的深耕細作,在數據積累方面擁有天然的優勢。據知乎去年第三季季績顯示,知乎社區內的內容量已累計超5.79億條,問答量累計超4.82億條,還有海量的用戶點贊投票數據,非常適合用於開發AIGC大模型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.